Updated Prostate Cancer Screening Guidelines Announced
Shared decision-making about screening recommended for men aged 55-69 years.
Shared decision-making about screening recommended for men aged 55-69 years.
Median survival time from diagnosis improved by a median of 43 months from the pre-PSA to the post-PSA era.
In fact, men on testosterone replacement therapy (TRT) had a lower PCa rate than men not on TRT.
Data support prophylactic use of a PDE-5 inhibitor in men receiving radiotherapy for prostate cancer.
This approach can reduce adverse events without impairing efficacy.
Study finds a significant inverse association between weight changes and incontinence scores in normal-weight patients.
New findings underscore the importance of achieve maximal tumor control in patients with high-risk disease.
Patients with pT4 tumors had five-year cancer-specific and overall survival rates of 91%.
After more than 10 years of follow-up, 54% of patients progressed, but only one patient died from prostate cancer.
Study reveals an elevated risk of lung cancer, which researchers called an intriguing finding.